On 1 February 2019 Marinomed Biotech AG celebrated its IPO at the Vienna Stock Exchange. At the event for the start of trading, the Marinomed management board team Pascal Schmidt (CFO), Eva Prieschl-Grassauer (CSO) and Andreas Grassauer (CEO) rang the bell together with Vienna Stock Exchange CEO Christoph Boschan.
Marinomed-Vorstand und Börsen-CEO
Marinomed-Vorstand: Schmidt, Prieschl-Grassauer & Grassauer
Marinomed-Vorstandsteam und Boschan im Innenhof
Vorstand beim Anschneiden der Torte
Marinomed-Vorstand und Börsen-CEO mit Börsenglocke
Marinomed-CEO Grassauer und Börsenvorstand Boschan
Note
- Click into the picture for a larger version.
- Click button "Download" to download the picture. The image in original size will open in a new window. Choose "Save image as..." with the right mouse button to save the picture.
- Download the whole gallery with the button at the end of the page. All pictures will be provided via zip-file.
Credit: Wiener Börse AG/APA-Fotoservice
| Company: Marinomed Biotech AG |
|---|
| ISIN: ATMARINOMED6 |
| Symbol: MARI |
| Trading Segment: Official Market |
| Market Segment: prime market |
| Category: no-par value bearer shares |
| Number of Shares (before IPO): 1,000,000 ordinary shares |
| Share Capital (before IPO): EUR 1,000,000.-- |
| First Day of Trading: 1 February 2019 |
| Offered Shares: up to 260,000 shares up to 40,000 shares (upsize option) up to 45,000 shares (greenshoe) |
| Offering Period: scheduled from 24 January 2019 until 29 January 2019 |
| Price Fixing: 29 January 2019 |
| Price Range: EUR 75.-- to EUR 90.-- |
| Offer Price: EUR 75,-- |
| Issuing Volume: EUR 19.5 million excl. greenshoe |
| Sole Global Coordinators, Underwriter and Sole Bookrunners: Erste Group Bank AG |
| Manager: goetzpartners securities Limited |
| Management Board: Andreas Grassauer Eva Prieschl-Grassauer Pascal Schmidt |
| Supervisory Board: Simon Nebel Ute Lassnig Karl Lankmayr Gernot Hofer Brigitte Ederer |
| Shareholder Structure (before IPO): Acropora Beteiligungs GmbH - 33.29% Hermann Unger - 13.03% Andreas Grassauer - 12.78% Eva Prieschl-Grassauer - 12.78% Invest Unternehmensbeteiligungs Aktiengesellschaft - 10.29% aws Mittelstandsfonds Beteiligungs GmbH & Co KG - 10.00% VETWIDI Forschungsholding GmbH - 3.96% Pascal Schmidt - 2.00% Helmut Baranyovszki - 0.87% Martin Platzer - 0.50% Angelika Bodenteich - 0.49% Total 100% |
| Address: Veterinärplatz 1 1210 Vienna T +43 (0)1 250774460 |
| Internet: www.marinomed.com |
About Marinomed Biotech AG
(Profile provided by the company)
Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners.
The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at www.marinomed.com.
Disclaimer
This website contains forward-looking statements and forecasts based on assumptions and expectations current at the time of publication. These forward-looking statements involve risks and uncertainties, and therefore, actual developments or events may turn out to be completely different from those expressed or implied by such statements. Forward-looking statements should not be understood as a guarantee of future developments or events, nor should readers place undue reliance on such statements. Wiener Börse AG does not assume any liability whatsoever for the forward-looking statements or forecasts, and actual events may differ materially from those expressed in these forward-looking statements or forecasts. The forward-looking statements in this press release are based on assumptions and expectations current at the time of publication and will not be updated at a later time. None of the information or statements on this website may be construed as a solicitation to buy or a recommendation to invest by Wiener Börse AG and neither can such information or statements serve as a basis for investment decisions in any country or for any person.